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Objectives The aim of this study was to investigate the impact of patient and lesion complexity on outcomes with newer-
generation zotarolimus-eluting stents (ZES) and everolimus-eluting stents (EES).
Background Clinical and angiographic outcomes of newer-generation stents have not been described among complex patients.
Methods Patients enrolled in the RESOLUTE All Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) were stratified into “complex” and
“simple.”
Results Of 2,292 patients, 1,520 (66.3%) were complex and treated with ZES (n  764) or EES (n  756). Event rates were
higher among complex patients, and results did not differ between ZES and EES, regardless of complexity. At 1 year,
target lesion failure was 8.9% in ZES- and 9.7% in EES-treated complex patients (p  0.66) and 6.8% in ZES- and
5.7% in EES-treated simple patients (p  0.55). Rates of cardiac death (1.3% vs. 2.2%, p  0.24), target-vessel myo-
cardial infarction (4.3% vs. 4.4%, p  0.90), and clinically indicated target lesion revascularization (4.4% vs. 4.0%,
p  0.80) were similar for both stent types among complex patients. Definite or probable stent thrombosis occurred
in 20 (1.3%) complex patients with no difference between ZES (1.7%) and EES (0.9%, p  0.26). Angiographic
follow-up showed similar results for ZES and EES in terms of in-stent percentage diameter stenosis (22.2  15.4% vs.
21.4  15.8%, p  0.67) and in-segment binary restenosis (6.6% vs. 8.0%, p  0.82) in the complex group.
Conclusions In this all-comers randomized trial, major adverse cardiovascular events were more frequent among complex
than simple patients. The newer-generation ZES and EES proved to be safe and effective, regardless of complex-
ity, with similar clinical and angiographic outcomes for both stent types through 1 year. (RESOLUTE-III All Com-
ers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percuta-
neous Coronary Intervention; NCT00617084) (J Am Coll Cardiol 2011;57:2221–32) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.036
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Newer-Generation DES in Complex Patients May 31, 2011:2221–32Drug-eluting stents (DES) are
currently used in complex patient
and lesion subsets in 60% to 70%
of cases (1,2). However, in light
of data available from random-
ized trials (3–5), the U.S. Food
and Drug Administration on-
label indication is limited to low-
risk patients with stable coronary
artery disease and simple single,
de novo lesions. Concerns re-
garding off-label use of DES
were raised mainly due to the
observation of higher rates of
stent thrombosis (ST) associated
with the unrestricted use of DES
(6) and its potential to offset
DES efficacy among more com-
plex patients treated outside randomized clinical trials.
Several studies and 1 meta-analysis with special focus on
DES safety showed less favorable outcomes of patients with
off-label compared with on-label indications with both
DES and bare-metal stents (BMS) related to the higher
clinical and angiographic complexity of off-label patients
(1,7–13). Notwithstanding, the higher efficacy of DES over
BMS was confirmed also in this high-risk patient subset,
with a substantial reduction in repeat revascularization and
without major concerns with respect to safety (1,7–15).
Most of the aforementioned studies were observational
and focused on early-generation DES, whereas the out-
comes of newer-generation DES have not been reported
among patients with complex clinical and angiographic
features. All-comers randomized clinical trials are per-
formed with the aim to investigate the safety and efficacy of
DES in a real-world population including the entire clinical
spectrum of patient and lesion complexity (16–19). The
recently published RESOLUTE All Comers trial (A Ran-
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
ECG  electrocardiogram/
electrocardiographic
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
ST  stent thrombosis
TLF  target lesion failure
TLR  target lesion
revascularization
ZES  zotarolimus-eluting
stent(s)Manuscript received November 9, 2010; revised manuscript received December 27,
010, accepted January 26, 2011.domized Comparison of a Zotarolimus-Eluting Stent With
an Everolimus-Eluting Stent for Percutaneous Coronary
Intervention) is the largest randomized DES all-comers trial
to date and showed noninferior clinical and angiographic
outcomes of the unrestricted use of the Resolute
zotarolimus-eluting stent (ZES) (Medtronic CardioVascu-
lar, Santa Rosa, California) compared with the XIENCE V
everolimus-eluting stent (EES) (Abbott Vascular Devices,
Santa Clara, California) (19). We performed a stratified
analysis of clinical and angiographic outcomes according to
patient and lesion complexity in the RESOLUTE All
Comers trial and compared the relative safety and efficacy of
ZES and EES in complex and simple patients.
Methods
Study population. The RESOLUTE All Comers trial is
an unrestricted, open-label, randomized, controlled, multi-
center trial (19). In brief the study applied an all-comers
approach to recruit 2,292 patients with chronic stable
coronary artery disease or acute coronary syndromes includ-
ing ST-segment elevation myocardial infarction (MI), who
were eligible for enrolment if they had 1 lesion with
diameter stenosis 50% and a reference vessel diameter
between 2.25 and 4.0 mm. No restriction was placed on the
number of lesions or vessels treated or the number of stents
implanted. Principal exclusion criteria were allergy to study
medication, metal alloys, or contrast media; planned surgery
within 6 months of percutaneous coronary intervention
(PCI) unless the dual antiplatelet therapy could be main-
tained throughout the peri-operative period; pregnancy;
participation in another trial before reaching the primary
endpoint; and inability to give informed consent.
The definition of complex patients was pre-specified and
included clinical and angiographic characteristics. Patients
were considered complex if they had at least 1 of the
following features: acute MI within 72 h, left ventricular
ejection fraction 30%, renal insufficiency or failure (creat-
inine 140 mol/l), treatment of bifurcations, saphenous
vein grafts, arterial grafts, in-stent restenosis, unprotected
left main lesions, more than 2 vessels treated, lesion length
27 mm, more than 1 lesion/vessel, lesions with thrombus,
or lesions with total occlusion (pre-procedure Thrombolysis
In Myocardial Infarction flow grade 0). The study complied
with the Declaration of Helsinki and was approved by all
institutional ethics committees. All patients provided writ-
ten, informed consent for participation in the trial.
Randomization and procedures. Patients were randomly
assigned on a 1:1 basis to treatment with either ZES or EES
and to 12-month clinical follow-up only or active angio-
graphic follow-up at 13 months, on a 4:1 basis with a
factorial design. A blinded independent clinical events
committee adjudicated all endpoints, and independent study
monitors verified all case reports from data on-site. The
operators were, by necessity, aware of the assigned study
stent during PCI and angiographic follow-up, but patients
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May 31, 2011:2221–32 Newer-Generation DES in Complex Patientsand staff involved in follow-up assessment were blinded to
the allocated stent type.
The ZES were available in diameters of 2.25 to 4.0 mm
and in lengths of 8 to 30 mm, whereas EES were
available in diameters of 2.25 to 4.0 mm and in lengths of
8 to 28 mm. Balloon angioplasty and stent implantation
were performed according to standard technique, and
direct stenting was allowed. The aim was to obtain full
lesion coverage with 1 or several stents. No mixture of
DES was permitted within a given patient, unless the
operator was unable to insert the study stent, in which
case crossover to another device of the operator’s choice
was possible.
Procedural anticoagulation was achieved with unfraction-
ated heparin 5,000 IU or 70 to 100 IU/kg or bivalirudin
0.75 mg/kg bolus followed by 1.75 mg/kg/h infusion. The
use of glycoprotein IIb/IIIa inhibitors was left to the
discretion of the operator. Before the procedure, all patients
enrolled into the study received at least 75 mg of acetylsal-
icylic acid, whereas the 300- to 600-mg loading dose of
clopidogrel was only given if no clopidogrel had been
administrated daily in the previous 7 days. All patients were
discharged on at least 75 mg of acetylsalicylic acid indefi-
nitely and clopidogrel 75 mg for 6 months after the index
procedure. In case of intercurrent revascularization proce-
Baseline Clinical Characteristics Stratified by ComplexityTable 1 Baseline Clinical Characteristics Stratified by Complex
Complex Pati
ZES
(n  764)
EES
(n  75
Age, yrs 64.0 11.1 63.7 1
Male 78.3% 79.6%
BMI, kg/m2 27.9 4.5 27.8 4
Cardiac risk factors
Hypertension 70.3% 69.6%
Hyperlipidemia 61.5% 64.7%
Diabetes mellitus 24.0% 22.2%
Insulin dependent 8.6% 6.7%
Current smoking 28.7% 30.3%
Premature CAD in first-degree relative 34.1% 36.8%
Previous MI 29.0% 30.2%
Previous PCI 33.5% 31.3%
Previous CABG 11.1% 10.6%
Clinical characteristics
Stable angina 27.1% 26.9%
Unstable angina 14.1% 15.1%
Acute MI within 72 h 43.2% 43.9%
ST-segment elevation MI 20.5% 24.6%
Non–ST-segment elevation MI 22.6% 19.3%
Left ventricular ejection fraction
30% 4.1% 3.4%
30%–50% 32.3% 32.1%
50% 63.6% 64.5%
Multivessel disease 61.6% 60.8%
Values are mean  SD or %.
BMI  body mass index; CABG  coronary artery bypass graft; CAD  coronary artery disease; EES  e
ZES  zotarolimus-eluting stent(s).dures requiring stent implantation, treating cardiologists
were encouraged to use study stents.
Adverse events were assessed in hospital, and clinical
follow-up was performed at 1, 6, and 12 months. Angio-
graphic follow-up at 13 months was planned in a random-
ized subset of patients (20%).
Quantitative coronary angiography. Quantitative coro-
nary angiography was performed with the CAAS II analysis
system (Pie Medical BV, Maastricht, the Netherlands).
Quantitative coronary angiography and SYNTAX score
calculation were centrally assessed at an angiographic core
laboratory (Cardialysis, Rotterdam, the Netherlands) (20).
dditional quantitative coronary angiography methodology
nd definitions are fully described elsewhere (19).
tudy endpoints. The primary endpoint of this analysis
as target lesion failure (TLF) at 12-month follow-up,
efined as a composite of cardiac death, target vessel MI,
nd clinically indicated target lesion revascularization
TLR). Secondary clinical endpoints were: a patient-
riented composite endpoint including all cause death, any
I, and any repeat revascularization; target vessel failure,
efined as a composite of cardiac death, target-vessel MI,
nd clinically indicated target vessel revascularization; the
ndividual components of the composite primary and sec-
ndary endpoints; and Academic Research Consortium–
Simple Patients
p Value
ZES
(n  376)
EES
(n  396) p Value
0.68 65.1 10.3 65.0 10.3 0.88
0.53 73.4% 72.5% 0.81
0.72 27.7 4.2 27.7 4.4 0.90
0.78 72.6% 74.5% 0.57
0.20 68.9% 73.5% 0.18
0.43 22.6% 25.8% 0.31
0.18 8.0% 7.8% 1.00
0.50 22.1% 19.2% 0.33
0.32 34.0% 36.5% 0.51
0.61 28.7% 31.0% 0.52
0.38 28.5% 33.6% 0.14
0.74 7.7% 7.6% 1.00
0.95 46.5% 53.8% 0.05
0.61 30.1% 26.3% 0.26
0.80 0.0% 0.0% —
0.07 0.0% 0.0% —
0.12 0.0% 0.0% —
0.74 0.43
0.0% 0.0%
26.8% 23.4%
73.2% 76.6%
0.75 51.9% 56.1% 0.25ity
ents
6)
1.0
.3verolimus-eluting stent(s); MI myocardial infarction; PCI  percutaneous coronary intervention;
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Newer-Generation DES in Complex Patients May 31, 2011:2221–32defined definite, probable, and overall ST at various time
points. The secondary angiographic endpoint was in-stent
percentage diameter stenosis. Additional angiographic mea-
sures included in-segment percentage diameter stenosis,
in-stent and in-segment minimal lumen diameter, late loss,
and binary restenosis.
All deaths were considered cardiac unless an undisputed
noncardiac cause was present. MI was defined according to
an extended historical definition (21). MI was considered
related to the target vessel unless clearly attributable to a
non-target vessel. A Q-wave MI required, in the absence of
cardiac enzyme data, a history of chest pain or other acute
symptoms consistent with myocardial ischemia together
with new pathological Q waves in 2 or more contiguous
electrocardiographic (ECG) leads as assessed by the core
laboratory or clinical events committee. In the presence of
elevated cardiac enzymes, new pathological Q waves in 2 or
more contiguous ECG leads as assessed by the core labo-
Baseline Lesion Characteristics Stratified by ComplexityTable 2 Baseline Lesion Characteristics Stratified by Complexi
Complex Pa
ZES
(n  1,227 Lesions) (n  1
Vessel location (per patient)
Left main 3.0%
Left anterior descending 53.1%
Left circumflex 34.0%
Right 39.7%
Bypass graft 3.7%
Saphenous vein graft 3.3%
Arterial graft 0.5%
ACC/AHA lesion class
A 2.0%
B1 17.7%
B2 27.0%
C 53.3%
Lesions with thrombus 7.3%
Ostial lesions 4.1%
Lesion with calcifications
Little or none 79.1%
Moderate-to-heavy 20.9%
TIMI flow grade
0 16.6%
1 3.1%
2 6.0%
3 74.4%
Angiographic measures
Lesion length, mm 12.11 8.30 12.
Reference vessel diameter, mm 2.61 0.59 2.
Minimal lumen diameter, mm 0.90 0.57 0.
Stenosis (% of lumen diameter) 65.5 19.8 66
Patient-based lesion characteristics
SYNTAX score 16.6 9.4 1
Patients with at least 1 bifurcation 25.1%
Patients with at least 1 in-stent restenosis 12.0%
Patients with at least 1 total occlusion 24.3%Values are % or mean  SD.
ACC/AHA  American College of Cardiology/American Heart Association; TIMI  Thrombolysis In Myoratory or clinical events committee were sufficient to diag-
nose a Q-wave MI. In the absence of an ECG, a Q-wave
MI could be adjudicated on the basis of the clinical scenario
and appropriate cardiac enzyme data. A revascularization
was considered clinically indicated if angiography during
follow-up showed a diameter stenosis 50% (core labora-
tory quantitative assessment) and if 1 of the following
occurred: 1) a positive history of recurrent angina pectoris,
presumably related to the target vessel; 2) objective signs of
ischemia at rest (ECG changes) or during exercise test (or
equivalent), presumably related to the target vessel; 3)
abnormal results of any invasive functional diagnostic test (e.g.,
fractional flow reserve); or 4) a TLR with a diameter stenosis
70% even in the absence of the aforementioned ischemic
signs or symptoms. Stent thrombosis was defined according to
the Academic Research Consortium criteria (22).
Statistical methods. The RESOLUTE All Comers trial
was powered for noninferiority testing of the primary
Simple Patients
esions) p Value
ZES
(n  434 Lesions)
EES
(n  463 Lesions) p Value
0.88 0.5% 1.3% 0.45
0.11 51.6% 48.0% 0.35
0.87 30.9% 31.6% 0.88
0.09 32.4% 36.1% 0.29
1.00 0.0% 0.0% —
0.68 0.0% 0.0% —
0.12 0.0% 0.0% —
0.71 0.32
2.3% 2.0%
28.0% 33.7%
35.0% 33.0%
34.7% 31.3%
0.68 0.0% 0.0% —
0.67 4.2% 2.2% 0.12
0.20 0.37
75.0% 77.6%
25.0% 22.4%
0.73 0.86
0.0% 0.0%
2.8% 3.7%
7.7% 6.3%
89.5% 90.0%
.83 0.21 11.38 5.16 11.18 5.12 0.56
.58 0.66 2.67 0.54 2.63 0.56 0.29
.55 0.44 1.11 0.39 1.07 0.41 0.17
9.6 0.42 58.2 12.2 59.1 12.7 0.31
9.4 0.94 11.2 7.9 10.9 7.5 0.64
0.41 0.0% 0.0% —
1.00 0.0% 0.0% —
0.41 0.0% 0.0% —ty
tients
EES
,242 L
3.2%
48.9%
33.6%
44.0%
3.7%
3.7%
0.0%
2.2%
19.0%
25.3%
53.4%
6.8%
3.8%
81.3%
18.7%
17.6%
2.7%
5.7%
73.9%
61 8
62 0
88 0
.1 1
6.5
27.0%
12.1%
26.2%cardial Infarction; other abbreviations as in Table 1.
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May 31, 2011:2221–32 Newer-Generation DES in Complex Patientsendpoint at 12 months on an intention-to-treat basis. For
full details of the sample size calculation with respect to the
noninferiority primary and secondary endpoints, we refer to
the main paper (19). The complex patient cohort was
defined according to the pre-specified definition. The sim-
ple patient cohort comprised all patients who were not
complex. For both complex and simple patients, patients
treated with ZES were compared with patients treated with
EES, and p values were calculated by Fisher exact test for
binary variables, Cochran-Mantel-Haenszel test for multi-
categorical variables, and t test for continuous variables. The
interaction p values were calculated for the clinical and
angiographic outcomes, with logistic regression or linear
regression, respectively. The time to the clinical endpoints
was calculated with the method of Kaplan-Meier. A 2-sided
p value 0.05 was considered statistically significant, unless
otherwise specified.
Results
Among 2,292 patients included in the RESOLUTE All
Comers trial, 1,520 were complex according to the pre-
specified definition, whereas 772 had simple characteristics.
Of 1,520 complex patients, 764 patients with 1,227 lesions
were allocated to treatment with ZES, and 756 patients
with 1,242 lesions were allocated to treatment with EES.
Of 772 simple patients, 376 patients with 434 lesions were
allocated to treatment with ZES, and 396 patients with 463
lesions were allocated to treatment with EES. Baseline
clinical variables were well-balanced between ZES and EES
among both complex and simple patients (Table 1). Com-
plex as compared with simple patients were younger (age
63.9  11.1 years vs. 65.1  10.3 years, p  0.008), more
requently male (78.9% vs. 72.9%, p  0.001) and smoking
29.5% vs. 20.6%, p  0.001), and had hyperlipidemia less
Procedural Results Stratified by ComplexityTable 3 Procedural Results Stratified by Complexity
Complex P
ZES E
Treated lesions/patient (index and staged), n 1.61 0.81 1.64
Patients with staged procedure, n 11.4% 12
Stents/lesion, n 1.15 0.41 1.20
Minimal stent diameter, mm 2.96 0.47 2.97
Stent length/lesion, mm 21.15 9.66 22.13
Maximal pressure/lesion, atm 14.92 3.16 15.09
Angiographic results
Final minimal lumen diameter, mm
In-stent 2.34 0.53 2.35
In-segment 2.03 0.54 2.04
Final stenosis, % of lumen diameter
In-stent 15.2 11.4 14.8
In-segment 23.6 12.2 23.3
Acute gain, mm
In-stent 1.44 0.61 1.48
In-segment 1.13 0.62 1.17Values are mean  SD or %.
Abbreviations as in Table 1.requently (63.1% vs. 71.2%, p  0.001) and previous
oronary artery bypass surgery more frequently (10.9% vs.
.6%, p  0.014). Target lesion and angiographic charac-
eristics at baseline revealed no differences between ZES
nd EES among complex and simple patients (Table 2).
rocedural and angiographic results are summarized in
able 3, showing similar outcomes for ZES and EES in
omplex and simple patients. Differences in clinical
ndication and angiographic characteristics including the
YNTAX score between complex and simple patients
ere driven by the pre-specified definition of complexity.
linical outcomes were obtained for 2,245 (97.9%) of the
,292 randomized patients during 1 year of follow-up.
wenty-one patients lost to follow-up belonged to the
ES group, and 26 patients belonged to the EES group.
linical outcomes. Rates of TLF (9.3% vs. 6.3%, p 
.015), target vessel failure (10.4% vs. 7.1%, p 0.009), and
he patient-oriented composite endpoint (16.1% vs. 11.6%,
 0.004) were higher among complex than simple
atients at 1 year.
Clinical events stratified for complexity are summarized
n Table 4. Among complex patients, the primary endpoint
LF—a composite of cardiac death, target-vessel MI, and
linically indicated TLR—was similar for both stent types,
ccurring in 67 (8.9%) ZES patients and 72 (9.7%) EES
atients (risk difference of 0.8% [95% confidence interval
CI): 3.7% to 2.2%]) (Fig. 1). Similarly, the patient-
riented endpoint—a composite of all-cause death, any MI,
nd any repeat revascularization—showed no difference
etween ZES- (15.6%) and EES-treated (16.6%) complex
atients (risk difference of 1.0% [95% CI: 4.7% to
.7%]) (Fig. 2). Rates of all-cause death were lower among
ES- than EES-treated complex patients at 1 year (1.5%
s. 3.4%, p 0.02), mainly driven by a significant difference
s Simple Patients
p Value ZES EES p Value
7 0.39 1.15 0.38 1.17 0.38 0.59
0.75 1.6% 3.8% 0.08
7 0.004 1.16 0.45 1.15 0.39 0.88
8 0.69 2.98 0.45 3.04 0.46 0.05
38 0.01 20.03 10.01 20.43 9.42 0.51
6 0.15 14.80 2.83 14.77 3.24 0.88
4 0.51 2.45 0.47 2.46 0.50 0.82
6 0.66 2.13 0.52 2.11 0.52 0.55
1 0.40 12.9 7.8 12.5 8.6 0.50
0 0.46 22.4 10.3 22.3 10.5 0.90
4 0.15 1.35 0.46 1.39 0.47 0.28
5 0.17 1.04 0.49 1.05 0.50 0.78atient
ES
 0.8
.0%
 0.4
 0.4
 10.
 3.1
 0.5
 0.5
 11.
 12.
 0.6
 0.6
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Newer-Generation DES in Complex Patients May 31, 2011:2221–32in noncardiac deaths (ZES: 0.1% vs. EES: 1.2%, p  0.01).
vent rates were similar for ZES- and EES-treated com-
lex patients with respect to cardiac death (1.3% vs. 2.2%,
 0.24), target-vessel MI (4.3% vs. 4.4%, p  0.90), and
linically indicated TLR (4.4% vs. 4.0%, p  0.80). Among
imple patients, rates of TLF (6.8% vs. 5.7%, risk difference
f 1.1% [95% CI: 2.4% to 4.6%, p  0.55]) and the
Clinical Events at 30 and 360 Days Stratified by ComplexityTable 4 Clinical Events at 30 and 360 Days Stratified by Comp
Complex Patients
ZES
(n  764)
EES
(n  756) Difference [95% CI]
Events at 30 days
Death 0.3% 1.2% 0.9% [1.8% to0.1%]
Cardiac death 0.3% 0.9% 0.7% [1.4% to 0.1%]
Target vessel MI 3.6% 4.0% 0.4% [2.4% to 1.5%]
Q-wave 0.5% 0.5% 0.0% [0.7% to 0.7%]
Non–Q-wave 3.2% 3.5% 0.3% [2.1% to 1.5%]
Non–target vessel MI 0.1% 0.1% 0.0% [0.4% to 0.4%]
Q-wave 0.1% 0.1% 0.0% [0.4% to 0.4%]
Non–Q-wave 0.0% 0.0% 0.0% [— to —]
Clinically indicated TLR 1.3% 0.7% 0.7% [0.3% to 1.6%]
Percutaneous 1.3% 0.4% 0.9% [0.0% to 1.8%]
Surgical 0.0% 0.3% 0.3% [0.6% to 0.1%]
Clinically indicated TVR 1.7% 0.9% 0.8% [0.4% to 1.9%]
Percutaneous 1.7% 0.7% 1.0% [0.0% to 2.1%]
Surgical 0.0% 0.3% 0.3% [0.6% to 0.1%]
Any revascularization 2.8% 2.1% 0.6% [0.9% to 2.2%]
Cardiac death or TV MI 3.8% 4.7% 0.8% [2.9% to 1.2%]
Death or TV MI 3.8% 4.9% 1.1% [3.2% to 1.0%]
TLF 4.5% 5.2% 0.7% [2.9% to 1.4%]
TVF 4.7% 5.5% 0.7% [2.9% to 1.5%]
Composite endpoint 5.9% 6.8% 0.9% [3.3% to 1.6%]
Events at 360 days
Death 1.5% 3.4% 1.9% [3.5% to0.4%]
Cardiac death 1.3% 2.2% 0.8% [2.2% to 0.5%]
Target vessel MI 4.3% 4.4% 0.2% [2.3% to 1.9%]
Q-wave 0.7% 0.5% 0.1% [0.7% to 0.9%]
Non–Q-wave 3.7% 3.9% 0.2% [2.1% to 1.8%]
Non–target vessel MI 0.3% 0.4% 0.1% [0.7% to 0.4%]
Q-wave 0.1% 0.1% 0.0% [0.4% to 0.4%]
Non–Q-wave 0.1% 0.3% 0.1% [0.6% to 0.3%]
Clinically indicated TLR 4.4% 4.0% 0.3% [1.7% to 2.4%]
Percutaneous 4.0% 3.2% 0.8% [1.1% to 2.6%]
Surgical 0.4% 0.9% 0.5% [1.4% to 0.3%]
Clinically indicated TVR 5.6% 5.5% 0.1% [2.3% to 2.4%]
Percutaneous 5.1% 4.9% 0.2% [2.0% to 2.4%]
Surgical 0.5% 1.1% 0.5% [1.5% to 0.4%]
Any revascularization 11.3% 10.1% 1.2% [1.9% to 4.3%]
Cardiac death or TV MI 5.5% 6.2% 0.7% [3.1% to 1.6%]
Death or TV MI 5.6% 7.4% 1.8% [4.3% to 0.7%]
TLF 8.9% 9.7% 0.8% [3.7% to 2.2%]
TVF 9.8% 11.1% 1.2% [4.3% to 1.9%]
Composite endpoint 15.6% 16.6% 1.0% [4.7% to 2.7%]
Values are %. *p values for interaction relate to differences in risk difference between complex a
CI  confidence interval; Composite endpoint  composite of death, myocardial infarction, a
infarction, clinically indicated target lesion revascularization); TLR  target lesion revascularizatio
infarction, clinically indicated target vessel revascularization); TVR  target vessel revascularizatiatient-oriented composite endpoint (12.5% vs. 10.7%, risk Zifference of 1.9% [95% CI: 2.7% to 6.4%, p  0.49])
ere comparable for ZES and EES, as were the individual
omponents of the primary endpoint (Table 4). Definite or
robable ST occurred in 20 (1.3%) complex patients with no
ignificant difference between ZES and EES (1.7% vs.
.9%, p  0.26). Among simple patients, definite or
robable ST was observed in 5 (1.4%) patients treated with
y
Simple Patients
p Value for
Interaction*e
ZES
(n  376)
EES
(n  396) Difference [95% CI] p Value
0.0% 0.3% 0.3% [0.8% to 0.2%] 1.00 0.97
0.0% 0.3% 0.3% [0.8% to 0.2%] 1.00 0.97
2.9% 3.0% 0.1% [2.5% to 2.3%] 1.00 0.86
0.3% 0.3% 0.0% [0.7% to 0.7%] 1.00 0.97
2.7% 2.8% 0.1% [2.4% to 2.2%] 1.00 0.92
0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.97
0.0% 0.0% 0.0% [— to —] — 1.00
0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.98
1.3% 0.8% 0.6% [0.9% to 2.0%] 0.49 0.90
0.8% 0.5% 0.3% [0.8% to 1.4%] 0.68 0.51
0.5% 0.3% 0.3% [0.6% to 1.2%] 0.61 0.97
1.3% 0.8% 0.6% [0.9% to 2.0%] 0.49 0.96
0.8% 0.5% 0.3% [0.8% to 1.4%] 0.68 0.64
0.5% 0.3% 0.3% [0.6% to 1.2%] 0.61 0.97
2.1% 1.3% 0.9% [1.0% to 2.7%] 0.41 0.69
2.9% 3.3% 0.4% [2.8% to 2.1%] 0.84 0.85
2.9% 3.3% 0.4% [2.8% to 2.1%] 0.84 0.76
3.8% 3.8% 0.1% [2.8% to 2.6%] 1.00 0.75
3.8% 3.8% 0.1% [2.8% to 2.6%] 1.00 0.76
4.6% 4.3% 0.2% [2.7% to 3.2%] 1.00 0.62
1.9% 1.6% 0.3% [1.5% to 2.2%] 0.78 0.11
1.4% 0.8% 0.6% [0.9% to 2.1%] 0.50 0.21
4.1% 3.4% 0.7% [2.0% to 3.4%] 0.70 0.60
0.8% 0.3% 0.6% [0.5% to 1.6%] 0.36 0.48
3.3% 3.1% 0.1% [2.4% to 2.7%] 1.00 0.84
0.8% 0.0% 0.8% [0.1% to 1.7%] 0.12 0.97
0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.97
0.5% 0.0% 0.5% [0.2% to 1.3%] 0.24 0.97
3.0% 2.1% 0.9% [1.3% to 3.2%] 0.49 0.59
2.2% 1.8% 0.4% [1.6% to 2.4%] 0.80 0.95
0.8% 0.3% 0.6% [0.5% to 1.6%] 0.36 0.13
3.5% 3.4% 0.2% [2.5% to 2.8%] 1.00 0.94
2.7% 3.1% 0.4% [2.8% to 2.0%] 0.83 0.71
0.8% 0.3% 0.6% [0.5% to 1.6%] 0.36 0.15
8.7% 7.0% 1.7% [2.2% to 5.5%] 0.42 0.73
5.2% 3.9% 1.3% [1.7% to 4.3%] 0.48 0.30
5.7% 4.4% 1.3% [1.8% to 4.4%] 0.51 0.15
6.8% 5.7% 1.1% [2.4% to 4.6%] 0.55 0.43
7.4% 6.8% 0.6% [3.1% to 4.3%] 0.78 0.51
12.5% 10.7% 1.9% [2.7% to 6.4%] 0.49 0.34
le patients.
scularization); TLF  target lesion failure (composite of cardiac death, target vessel myocardial
target vessel; TVF  target vessel failure (composite of cardiac death, target vessel myocardial
r abbreviations as in Table 1.lexit
p Valu
0.04
0.11
0.69
1.00
0.77
1.00
1.00
—
0.30
0.09
0.25
0.26
0.09
0.25
0.51
0.44
0.31
0.55
0.56
0.53
0.02
0.24
0.90
1.00
0.89
0.68
1.00
0.62
0.80
0.49
0.22
1.00
0.90
0.26
0.50
0.58
0.17
0.66
0.45
0.62
nd simp
ny revaES and 1 (0.3%) patient treated with EES (p  0.12).
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May 31, 2011:2221–32 Newer-Generation DES in Complex PatientsRates of definite, definite or probable, and overall ST at
various time points are summarized in Table 5. The mean
duration of dual antiplatelet therapy was similar among
complex (ZES: 329.6 74.1 days; EES: 324.9 79.4 days,
p  0.24) and simple patients (ZES: 325.7  80.3 days;
EES: 330.6  69.9 days, p  0.37). Of note: of 16 patients
suffering definite ST, there was only 1 case of a complex
patient treated with ZES who had discontinued clopidogrel
3 days before ST.
Angiographic outcomes. Angiographic follow-up at 13
months was obtained in 137 complex ZES and 138 complex
EES lesions as well as in 54 simple ZES and 48 simple EES
lesions. Quantitative coronary angiographic findings during
follow-up are shown in Table 6. Among lesions in complex
atients, the secondary angiographic endpoint in-stent per-
entage diameter stenosis (ZES: 22.2  15.4% vs. EES: 21.4
15.8%, p  0.67) as well as in-stent late loss (ZES: 0.26 
0.48 mm vs. EES: 0.23 0.44 mm, p 0.75) and in-segment
inary restenosis (6.6% vs. 8.0%, p  0.82) were similar for
ES and EES. Conversely, in-stent percentage diameter
tenosis (20.2  11.6 vs. 15.0  9.0, p  0.01) and in-stent
ate loss (0.29  0.27 vs. 0.07  0.25, p  0.001) were lower
ith EES than ZES among lesions in simple patients, al-
hough formal tests for interaction failed to reach conventional
Figure 1 Target Lesion Failure Stratified for Complexity and St
Kaplan-Meier cumulative incidence of target lesion failure—composite of cardiac d
target lesion revascularization stratified according to complexity and stent type. EEevels of significance (Fig. 3). In-segment binary restenosis in aesions of simple patients was low and comparable for both
tent types (1.9% vs. 2.1%, p  1.00).
iscussion
his is the first report investigating the impact of patient
nd lesion complexity on clinical and angiographic out-
omes with the unrestricted use of 2 newer-generation DES
n a large-scale, randomized clinical trial. The findings can
e summarized as follows:
1. Newer-generation DES are safe and effective among
patients with complex baseline clinical and angio-
graphic characteristics through 1 year.
2. The ZES and EES achieve similar clinical outcomes,
regardless of patient complexity through 1 year.
3. The ZES and EES yield similar angiographic results
particularly among complex patients.
4. Newer-generation DES are associated with low rates
of ST in both complex and simple patient populations.
Several studies investigating the safety and effectiveness of
arly-generation DES in complex patients with off-label char-
cteristics showed a less-favorable outcome compared with
atients with simple on-label features (7–15). A large meta-
ype
target vessel myocardial infarction, and clinically indicated
verolimus-eluting stent(s); ZES  zotarolimus-eluting stent(s).ent T
eath,
S  enalysis confirmed the higher efficacy of DES over BMS
2228 Stefanini et al. JACC Vol. 57, No. 22, 2011
Newer-Generation DES in Complex Patients May 31, 2011:2221–32Figure 2 Patient-Oriented Composite Endpoint Stratified for Complexity and Stent Type
Kaplan-Meier cumulative incidence of the patient-oriented composite endpoint—composite of all-cause death, myocardial infarction, and repeat revascularization
stratified according to complexity and stent type. Abbreviations as in Figure 1.ARC-Defined ST Stratified by ComplexityTable 5 ARC-Defined ST Stratified by Complexity
Complex Patients Simple Patients
p Value for
Interaction*
ZES
(n  764)
EES
(n  756) Difference [95% CI] p Value
ZES
(n  376)
EES
(n  396) Difference [95% CI] p Value
Definite ST
Acute 0.4% 0.1% 0.3% [0.3% to 0.8%] 0.62 0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.98
Subacute 0.5% 0.0% 0.5% [0.0% to 1.1%] 0.12 0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 1.00
Early 0.9% 0.1% 0.8% [0.1% to 1.5%] 0.07 0.5% 0.0% 0.5% [0.2% to 1.3%] 0.24 0.97
Late 0.4% 0.3% 0.1% [0.5% to 0.7%] 1.00 0.5% 0.0% 0.5% [0.2% to 1.3%] 0.24 0.97
Overall 1.2% 0.4% 0.8% [0.1% to 1.7%] 0.14 1.1% 0.0% 1.1% [0.0% to 2.2%] 0.06 0.98
Definite or probable ST
Acute 0.5% 0.3% 0.3% [0.4% to 0.9%] 0.69 0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.98
Subacute 0.9% 0.4% 0.5% [0.3% to 1.4%] 0.34 0.3% 0.3% 0.0% [0.7% to 0.7%] 1.00 0.61
Early 1.3% 0.7% 0.7% [0.4% to 1.7%] 0.30 0.5% 0.3% 0.3% [0.6% to 1.2%] 0.62 0.97
Late 0.5% 0.3% 0.3% [0.4% to 0.9%] 0.69 0.8% 0.0% 0.8% [0.1% to 1.7%] 0.12 0.97
Overall 1.7% 0.9% 0.8% [0.4% to 1.9%] 0.26 1.4% 0.3% 1.1% [0.2% to 2.4%] 0.12 0.38
Definite, probable, or possible ST
Acute 0.5% 0.3% 0.3% [0.4% to 0.9%] 0.69 0.3% 0.0% 0.3% [0.3% to 0.8%] 0.49 0.98
Subacute 0.9% 0.4% 0.5% [0.3% to 1.4%] 0.34 0.3% 0.3% 0.0% [0.7% to 0.7%] 1.00 0.61
Early 1.3% 0.7% 0.7% [0.4% to 1.7%] 0.30 0.5% 0.3% 0.3% [0.6% to 1.2%] 0.62 0.98
Late 1.2% 1.3% 0.2% [1.3% to 1.0%] 0.82 1.6% 0.3% 1.4% [0.0% to 2.8%] 0.06 0.09
Overall 2.4% 2.0% 0.4% [1.1% to 1.9%] 0.73 2.2% 0.5% 1.7% [0.0% to 3.3%] 0.06 0.14Values are %. *p values for interaction relate to differences in risk difference between complex and simple patients.
ARC  Academic Research Consortium; ST  stent thrombosis; other abbreviations as in Tables 1 and 4.
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May 31, 2011:2221–32 Newer-Generation DES in Complex Patientsamong off-label patients, with a substantial reduction in the
risk of target vessel revascularization (hazard ratio: 0.45, p 
.001) and no concern with respect to safety (1), although most
f these data were observational and limited to early-
eneration DES. More recently, the newer-generation EES
as been shown to improve upon the safety and efficacy profile,
ompared with the early-generation paclitaxel-eluting stent,
nd the newer-generation ZES has been shown to be nonin-
erior to EES (18,23). However, no study has focused on the
ifferential outcome of newer-generation DES among patients
ith complex clinical and angiographic characteristics typically
xcluded from pre-approval DES trials.
Against this background, we compared clinical and an-
iographic outcomes between ZES and EES among com-
lex as well as simple patients included in the RESOLUTE
ll Comers trial. In this largest all-comers study, the
nrestricted use of ZES and EES was tested in patients
overing a wide range of clinical and angiographic complex-
ties. The pre-specified definition of complex patients en-
ompassed real-world characteristics, including acute MI
ithin 72 h, left ventricular ejection fraction 30%, renal
nsufficiency or failure, treatment of bifurcations, saphenous
ein grafts, arterial grafts, in-stent restenosis, unprotected
eft main lesions, more than 2 vessels treated, lesion length
27 mm, more than 1 lesion/vessel, lesion with thrombus,
r lesion with total occlusion.
This definition is well in line with previous reports, as is
he proportion of complex patients compared with previ-
usly reported all-comers populations (Fig. 4A). Two-
hirds of patients included in the RESOLUTE All Comers
rial were complex, indicating that indeed the majority of
atients undergoing PCI in routine clinical practice include
hose typically excluded from pre-approval DES trials.
nsurprisingly, event rates were higher among complex
ompared with simple patients, owing to the higher preva-
ence of unfavorable prognostic indicators such as acute
oronary syndromes, lower left ventricular ejection fraction,
mpaired renal function, and complex angiographic charac-
eristics as evidenced by the higher SYNTAX score (24,25).
he risk of TLF and the patient-oriented composite endpoint
as increased by approximately one-third—comparing com-
lex with simple patients. Event rates associated with the
se of ZES and EES among complex and simple patients
ere largely comparable across all endpoints, with the
xception of all-cause mortality among complex patients.
owever, the higher 1-year mortality associated with EES-
reated complex patients was mainly due to a significantly
igher rate of noncardiac deaths, whereas differences in
erms of cardiac death were less pronounced.
The similar outcome between ZES and EES in terms of
linically indicated TLR and target vessel revascularization
mong complex patients is supported by the angiographic
ndings with similar in-stent minimal lumen diameter,
ercentage diameter stenosis, late loss, and in-segment
inary restenosis at 13 months. Conversely, angiographicparameters including in-stent minimal lumen diameter,An T
R M S L B
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Newer-Generation DES in Complex Patients May 31, 2011:2221–32percentage diameter stenosis, and late loss were in favor of
EES among simple patients. Although formal tests for
interaction reached conventional levels of significance for
minimal lumen diameter, we consider these findings most
likely due to chance and the low number of simple patients
undergoing angiographic follow-up, because any differential
outcome between the 2 devices would have been anticipated
among complex patients. The favorable angiographic out-
come even among complex patients with both newer-
generation DES is of importance. Thus, previous studies
comparing early-generation DES with surgical revascular-
ization have shown similar outcomes in terms of safety but
an increased risk of repeat revascularization among patients
with 3-vessel as well as left main disease (24,25). Several
randomized trials comparing EES with paclitaxel-eluting
stent and an observational propensity score-matched com-
parison of EES with sirolimus-eluting stents have shown a
lower risk of repeat revascularization with the newer-
generation DES. Accordingly, the 2 newer-generation DES
included in the present study might further improve on the
efficacy profile of early-generation DES without compro-
mising safety, which is of particular importance among
complex patients and for future comparative trials against
coronary artery bypass surgery (Fig. 4B).
Low rates of definite as well as definite or probable ST
events were observed in the overall population (19), and
Figure 3 Stent Percentage Diameter Stenosis Stratified for Co
Cumulative frequency of in-stent percentage diameter stenosis stratified for stent
Abbreviations as in Figure 1.EES was associated with a lower rate of ST, as comparedwith ZES. The present analysis points out that rates of ST
were also low among complex patients, with overall 12
definite (0.8%) and 20 (1.3%) definite or probable events.
Although there was no statistically significant difference
between stent types, event rates for ST were numerically
lower with EES than ZES. However, estimates of risk
differences were imprecise—with wide CIs—suggesting in-
adequate power to detect potential differences between stent
types in this subgroup analysis. Moreover, event rates for
cardiac death or target vessel MI were similar for EES and
ZES, suggesting that any potential difference in terms of ST
failed to translate into differences in ischemic outcomes.
Among simple patients, due to the very few events ob-
served—4 definite and 6 definite or probable ST—it is
difficult to interpret these findings. Overall, comparing
event rates of definite ST in the present study with previ-
ously reported all-comers patient populations at 1 year, we
observed event rates below 1%, which seem acceptable given
the complexity of included patients and certainly testify to
the progress in reducing this adverse event among patients
undergoing PCI in contemporary practice (Fig. 4C).
Study limitations. The results of the present study have to be
interpreted in light of the following limitations. The present
report is a subgroup analysis of a randomized trial not exclu-
sively dedicated to complex patients and was not adequately
powered to detect treatment–subgroup interactions. However,
ity and Stent Type
exity and stent type at 13-month angiographic follow-up.mplex
complpatient and lesion characteristics were similar between ZES-
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(A) Frequency of drug-eluting stents implantation among patients with at least 1 off-label characteristic in published reports. (B) Rate of clinically driven target lesion
revascularization at 12 months with drug-eluting stents in published all comers randomized clinical trials. The rate of protocol-mandated angiographic follow-up differed
somewhat between the studies and were as follows: SIRTAX (Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization): 53%; LEADERS (Limus Eluted
From A Durable Versus ERodable Stent Coating): 20%; COMPARE (A Randomized Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary
Revascularization in Daily Practice): no angiographic follow-up; and RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent
for Percutaneous Coronary Intervention): 12%. (C) Rate of definite stent thrombosis at 12 months with drug-eluting stents in published all-comers randomized clinical
trials.
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bias. Moreover, the clinical findings are buttressed by consis-
tent observations among patients undergoing angiographic
follow-up. Therefore, we consider it unlikely that the results
would change in larger patient cohorts. Another limitation is
the varying degree of patient and lesion complexity within the
complex cohort. Thus, patients undergoing multivessel PCI in
the setting of an acute MI and reduced left ventricular function
were represented in the same group as a patient undergoing
PCI of a single long lesion. However, individual clinical and
angiographic characteristics defining the complex cohort of the
present study have all been shown to portend a worse progno-
sis, and pooling of all patients in a single cohort provides
improved statistical power to detect differences between the 2
devices. The data provided in this report are limited to 1 year,
and therefore the present study cannot address the issue of very
late ST—the principal shortcoming of the unrestricted use of
early-generation DES. Annual follow-up to 5 years, as speci-
fied in the protocol, will address this concern in future
investigations. Finally, differences in ST between ZES and
EES emerged in the overall population but were diminished in
the stratified analysis of complex and simple patients. We
cannot exclude potential differences between the 2 devices with
certainty, due to the low event rates. However, the similar
outcomes in terms of cardiac death and MI call into question
the relative importance of ST as an isolated event with the use
of newer-generation DES.
Conclusions
In this all-comers randomized clinical trial, major adverse
cardiovascular events were more frequent among complex
than simple patients. The newer-generation ZES and EES
were shown to be safe and effective, regardless of complex-
ity, with similar clinical and angiographic outcomes for both
stent types through 1 year.
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